ReviewBioMed research international2013
Application of nanoparticles on diagnosis and therapy in gliomas.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 83 citations in OpenAlex.
- Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025Review
- Review
- New insights into targeted therapy of glioblastoma using smart nanoparticles.Cancer cell international · 2024Review
- Platinum-Based Nanoformulations for Glioblastoma Treatment: The Resurgence of Platinum Drugs?Nanomaterials (Basel, Switzerland) · 2023Review
- Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.Molecules (Basel, Switzerland) · 2023Review
- Application of nanomedicine in radiotherapy sensitization.Frontiers in oncology · 2023Review
- Transcription Factors with Targeting Potential in Gliomas.International journal of molecular sciences · 2022Review
- Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System.Frontiers in medicine · 2021Review
- Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma.Molecules (Basel, Switzerland) · 2020Review
- Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs.Frontiers in neuroscience · 2020Review
- Enhanced Anti-Glioma Efficacy by Borneol Combined With CGKRK-Modified Paclitaxel Self-Assembled Redox-Sensitive Nanoparticles.Frontiers in pharmacology · 2020Article
- Harnessing Microglia and Macrophages for the Treatment of Glioblastoma.Frontiers in pharmacology · 2019Review
- Imaging Gliomas with Nanoparticle-Labeled Stem Cells.Chinese medical journal · 2018Review
- Application of dual targeting drug delivery system for the improvement of anti-glioma efficacy of doxorubicin.Oncotarget · 2017Article
- Development and Characterization of Methylene Blue Oleate Salt-Loaded Polymeric Nanoparticles and their Potential Application as a Treatment for Glioblastoma.Journal of nanomedicine & nanotechnology · 2017Article
- Cytotoxicity induced by carbon nanotubes in experimental malignant glioma.International journal of nanomedicine · 2017Article
- Survival in glioblastoma: a review on the impact of treatment modalities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Review
- Efficiency of calcium phosphate composite nanoparticles in targeting Ehrlich carcinoma cells transplanted in mice.Journal of advanced research · 2016Article
- Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.Journal of neuro-oncology · 2015Review
- Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma.Drug design, development and therapy · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme (GBM) is one of the most deadly diseases that affect humans, and it is characterized by high resistance to chemotherapy and radiotherapy. Its median survival is only fourteen months, and this dramatic prognosis has stilled without changes during the last two decades; consequently GBM remains as an unsolved clinical problem. Therefore, alternative diagnostic and therapeutic approaches are needed for gliomas. Nanoparticles represent an innovative tool in research and therapies in GBM due to their capacity of self-assembly, small size, increased stability, biocompatibility, tumor-specific targeting using antibodies or ligands, encapsulation and delivery of antineoplastic drugs, and increasing the contact surface between cells and nanomaterials. The active targeting of nanoparticles through conjugation with cell surface markers could enhance the efficacy of nanoparticles for delivering several agents into the tumoral area while significantly reducing toxicity in living systems. Nanoparticles can exploit some biological pathways to achieve specific delivery to cellular and intracellular targets, including transport across the blood-brain barrier, which many anticancer drugs cannot bypass. This review addresses the advancements of nanoparticles in drug delivery, imaging, diagnosis, and therapy in gliomas. The mechanisms of action, potential effects, and therapeutic results of these systems and their future applications in GBM are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.